Search

Your search keyword '"Fabris, Paolo"' showing total 4 results
Start Over Author "Fabris, Paolo" Topic interferons
4 results on '"Fabris, Paolo"'

1. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection.

Author

Betterle, Corrado, Fabris, Paolo, Zanchetta, Renato, Pedini, Beniamino, Tositti, Giulia, Bosi, Emanuele, De Lalla, Fausto, Betterle, C, Fabris, P, Zanchetta, R, Pedini, B, Tositti, G, Bosi, E, and de Lalla, F

Subjects
*HEPATITIS C virus, *INTERFERONS, *DIABETES complications, *ITALIANS, *HEALTH, *PHYSIOLOGY
Abstract

Objective: The aim of the study was to investigate the prevalence of clinical and latent autoimmune diseases in Italian patients with hepatitis C virus (HCV) chronic infection before and after treatment with interferon-alpha (IFN-alpha).Research Design and Methods: The evidence of clinical autoimmune disease and the presence of autoantibodies were assessed in 70 patients with HCV chronic infection. Autoantibodies to islet cell (ICA), glucagon-producing cells (GCA), parietal cell (PCA), adrenal cortex (ACA), adrenal medulla (AdMA), nuclei (ANA), liver-kidney microsomal (LKM-Ab), mitochondrial, and smooth muscle (SMA) were tested using the classic indirect immunofluorescence technique. Autoantibodies to GAD (GADAb), second islet cell autoantigen (IA2-Ab), and insulin (IAA) were tested by radioimmunoassay and thyroid microsomal autoantibodies (TMHA) and thyroglobulin autoantibodies (TGHA) were assessed by hemoagglutination test.Results: None of the 70 patients studied showed evidence of clinical disease before treatment with IFN-alpha. However, 1 (1.4%) patient was positive for ICA, 2 (2.8%) were positive for GCA, 2 (2.8%) for GADAb, 5 (7.1%) for PCA, 2 (2.8%) for ANA, 3 (3.7%) for SMA, 4 (5.7%) for TMHA, and 2 (2.8%) for TGHA. These frequencies were not significantly different when compared with healthy control subjects. There were 29 (41%) patients who were positive for IAA at low titers compared with 2% of the control subjects (significantly different P < 0.0001). ICA titers of one patient positive for ICA/GADAb increased during the IFN-alpha therapy, and the patient developed type 1 diabetes 5 months after the beginning of treatment. IAA levels did not change during the course of treatment, and none of the IAA+ patients developed diabetes. Thyroid autoantibody titers increased in 3 of the 4 initially positive patients, with 1 patient becoming positive and 2 thyroid antibody-positive patients developing overt hypothyroidism during IFN-alpha treatment. PCA titers increased in 1 of 5 positive patients. Antibodies to other autoantigens did not change during the course of treatment.Conclusions: We have not found an increased frequency of clinical or latent autoimmune diseases in patients with chronic HCV infection. However, this study suggests that screening patients for autoantibodies (in particular, thyroid and pancreas) before and during IFN-alpha therapy may be useful in assessing the risk of patients developing autoimmune disease. [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

2. Successfull Response to alpha 2b Interferon plus Ribavirin associated with Venesectomies in a Patient with Chronic Hepatitis C and Genetic Hemochromatosis.

Author

Fabris, Paolo, Tositti, Giulia, Giordani, Maria Teresa, and de Lalla, Fausto

Subjects
*INTERFERONS, *RIBAVIRIN, *HEMOCHROMATOSIS, *HEPATITIS C treatment, *THERAPEUTICS
Abstract

Discusses the use of alpha-interferon plus ribavirin to treat patients with genetic hemochromatosis and chronic hepatitis C. Venesectomies; Blood testing; Virological testing.

Published
2003
Full Text
View/download PDF

3. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.

Author

Arcaini, Luca, Besson, Caroline, Frigeni, Marco, Fontaine, Hélène, Goldaniga, Maria, Casato, Milvia, Visentini, Marcella, Torres, Harrys A., Loustaud-Ratti, Veronique, Peveling-Oberhag, Jan, Fabris, Paolo, Rossotti, Roberto, Zaja, Francesco, Rigacci, Luigi, Rattotti, Sara, Bruno, Raffaele, Merli, Michele, Dorival, Céline, Alric, Laurent, and Jaccard, Arnaud

Subjects
*CHRONIC lymphocytic leukemia, *LYMPHOPROLIFERATIVE disorders, *HEPATITIS C virus, *INTERFERONS, *ANTIVIRAL agents, *WALDENSTROM'S macroglobulinemia
Abstract

Regression of hepatitis C virus (HCV)-associated lymphoma with interferon (IFN)-based antiviral treatment supports an etiological link between lymphoma and HCV infection. In addition, a favorable impact of antiviral treatment on overall survival of patients with HCV-related lymphoma has been reported. Data on IFN-free regimens combining direct-acting antivirals (DAAs) in HCV-associated lymphoproliferative disorders are scanty. We analyzed the virological and lymphoproliferative disease response (LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHLs) or chronic lymphocytic leukemia (CLL) and chronic HCV infection treated with DAAs. The histological distribution was 37 marginal zone lymphomas (MZLs), 2 lymphoplasmacytic lymphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade NHL not otherwise specified. Thirty-nine patients received a sofosbuvir-based regimen and 7 patients received other DAAs. The median duration of DAA therapy was 12 weeks (range, 6-24 weeks). A sustained virological response at week 12 after finishing DAAs was obtained in 45 patients (98%); the overall LDR rate was 67%, including 12 patients (26%) who achieved a complete response. The LDR rate was 73% among patients with MZL, whereas no response was observed in CLL/SLL patients. Seven patients cleared cryoglobulins out of 15 who were initially positive. After a median follow-up of 8 months, 1-year progression-free and overall survival rates were 75% (95% confidence interval [CI], 51-88] and 98% [95% CI, 86-100], respectively. DAA therapy induces a high LDR rate in HCV-associated indolent lymphomas. These data provide a strong rationale for prospective trials with DAAs in this setting. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

4. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Author

Virginia Valeria Ferretti, Stanislas Pol, Harrys A. Torres, Hélène Fontaine, Marcella Visentini, Arnaud Jaccard, Sara Rattotti, Laurent Alric, Milvia Casato, Carlo Visco, Véronique Loustaud-Ratti, Paolo Fabris, Luigi Rigacci, Luca Arcaini, Marco Frigeni, Roberto Rossotti, Fabrice Carrat, Francesco Zaja, Raffaele Bruno, Céline Dorival, Jan Peveling-Oberhag, Michele Merli, Maria Goldaniga, Olivier Hermine, Caroline Besson, Università degli Studi di Pavia = University of Pavia (UNIPV), Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), The University of Texas M.D. Anderson Cancer Center [Houston], CHU Limoges, Goethe-Universität Frankfurt am Main, Ospedale San Bortolo, Ospedale Niguarda, Azienda Ospedaliera Universitaria Santa Maria della Misericordia, Udine, Italy., Azienda Ospedaliero-Universitaria Careggi (AOUC), Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Universitá degli Studi dell’Insubria = University of Insubria [Varese] (Uninsubria), Epidémiologie, Systèmes d'Information, Modélisation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Necker - Enfants Malades [AP-HP], CTG repeat instability and myotonic dystrophy (Equipe Inserm U1163), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), The ANRS-CO22 HEPATHER cohort was sponsored and funded by The French Research Agency ANRS (France REcherche Nord&Sud Sida-HIV Hépatites)., University of Pavia, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], University of Insubria, Varese, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Institut de Recherche pour le Développement (IRD), Arcaini, Luca, Besson, Caroline, Frigeni, Marco, Fontaine, Hélène, Goldaniga, Maria, Casato, Milvia, Visentini, Marcella, Torres, Harrys A, Loustaud Ratti, Veronique, Peveling Oberhag, Jan, Fabris, Paolo, Rossotti, Roberto, Zaja, Francesco, Rigacci, Luigi, Rattotti, Sara, Bruno, Raffaele, Merli, Michele, Dorival, Céline, Alric, Laurent, Jaccard, Arnaud, Pol, Stanisla, Carrat, Fabrice, Ferretti, Virginia Valeria, Visco, Carlo, and Hermine, Olivier

Subjects
Male, Sofosbuvir, Chronic lymphocytic leukemia, [SDV]Life Sciences [q-bio], medicine.disease_cause, Biochemistry, Gastroenterology, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, b-lymphocytes, Chronic, hepatitis c, treatment, lymphoproliferative disorders, Hematology, Hepatitis C, Middle Aged, small cell lymphoma, Immunology, Cell Biology, 3. Good health, virology, Survival Rate, interferons, 030220 oncology & carcinogenesis, HCV, Female, 030211 gastroenterology & hepatology, lymphoproliferative disorder, medicine.drug, medicine.medical_specialty, Lymphoma, B-Cell, human leukocyte interferon, Hepatitis C virus, Lymphoproliferative disorders, lymphoma, Disease-Free Survival, 03 medical and health sciences, Internal medicine, antiviral agents, medicine, Humans, Survival rate, Retrospective Studies, business.industry, B-Cell, Hepatitis C, Chronic, hepatitis c virus, medicine.disease, Antiviral Agents, Lymphoma, Regimen, business
Abstract

International audience; Regression of hepatitis C virus (HCV)-associated lymphoma with interferon (IFN)-based antiviral treatment supports an etiological link between lymphoma and HCV infection. In addition, a favorable impact of antiviral treatment on overall survival of patients with HCV-related lymphoma has been reported. Data on IFN-free regimens combining direct-acting antivirals (DAAs) in HCV-associated lymphoproliferative disorders are scanty. We analyzed the virological and lymphoproliferative disease response (LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHLs) or chronic lymphocytic leukemia (CLL) and chronic HCV infection treated with DAAs. The histological distribution was 37 marginal zone lymphomas (MZLs), 2 lymphoplasmacytic lymphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade NHL not otherwise specified. Thirty-nine patients received a sofosbuvir-based regimen and 7 patients received other DAAs. The median duration of DAA therapy was 12 weeks (range, 6-24 weeks). A sustained virological response at week 12 after finishing DAAs was obtained in 45 patients (98%); the overall LDR rate was 67%, including 12 patients (26%) who achieved a complete response. The LDR rate was 73% among patients with MZL, whereas no response was observed in CLL/SLL patients. Seven patients cleared cryoglobulins out of 15 who were initially positive. After a median follow-up of 8 months, 1-year progression-free and overall survival rates were 75% (95% confidence interval [CI], 51-88] and 98% [95% CI, 86-100], respectively. DAA therapy induces a high LDR rate in HCV-associated indolent lymphomas. These data provide a strong rationale for prospective trials with DAAs in this setting.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results